Identifikasi Drug-Related Problems (DRPs) Pada PasienSirosis Hepatik Berdasarkan Pcne V9.1 Di RSUD IncheAbdoel Moeis Samarinda
Identification of Drug-Related Problems (DRPs) Using PCNE V9.1 On Hepatic Cirrhosis Patients at Inche Abdoel Moeis Hospital Samarinda
DOI:
https://doi.org/10.30872/mpc.v19i.487Keywords:
Hepatic Cirrhosis, DRPs, PCNE V9.1Abstract
Hepatic cirrhosis is a chronic liver disorder characterized by structural damage, scar formation, and regenerative nodules. It often involves complications and polypharmacy, increasing the risk of Drug-Related Problems (DRPs). This study aimed to identify DRPs using the Pharmaceutical Care Network Europe (PCNE) V9.1 classification among patients at Inche Abdoel Moeis Hospital, Samarinda. A total of 30 patients met the inclusion criteria. Most were male, totaling 22 patients (73%), and the most common age group was 56–65 years, with 14 patients (47%). The most frequent complication was ascites, affecting 21 patients (70%). The most commonly prescribed medications were diuretics, specifically spironolactone and furosemide (70%). According to PCNE V9.1, the most frequent DRP was in domain C1.1, related to inappropriate drug use according to guidelines, including errors in variceal bleeding therapy and antibiotic administration, occurring in 3 patients (10%).
References
[1] Y. B. Liu and M. K. Chen, “Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions,” World journal of gastroenterology, vol. 28, no. 41, pp. 5910-5930, 2022.
[2] A. M. Moon, A. G. Singal and E. B. Tapper, “Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis,” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol. 18, no. 12, pp. 2650-2666, 2020.
[3] R. Thaha, E. Yunita and M. Sabir, “Sirosis Hepatis,” Jurnal Medical Proffesion, vol. 2, no. 3, 2020.
[4] A. N. A. Harahap, S. Miro, E. Usman, D. Elvira, R. Yaswir and R. Suswita, “Korelasi antara Diameter Limpa dengan Jumlah Trombosit pada Pasien Sirosis Hati,” Majalah Kedokteran Andalas, vol. 46, no. 10, pp. 1578-1591, 2023.
[5] S. G. Virma, P. Adelin and L. Mona, “Karakteristik Pasien Sirosis hepatis di Rumah Sakit Dr Achmad Mochtar Bukittinggi Periode Tahun 2018-2020,” Jurnal Kedokteran Nanggroe Medika, vol. 6, no. 1, pp. 1-8, 2023.
[6] H. A. Wardani, H. Stevani and Syachriani, “Faktor-Faktor Risiko Terhadap Kejadian Drug Related Problems (DRPs) Pada Pasien Sirosis Hepatik,” Media Farmasi, vol. 16, no. 1, pp. 49-56, April 2020.
[7] M. H. Tarigan, “Fenomena Penelitian Drug Related Problems pada Jurnal Farmasi di Indonesia: dari Kriteria Pasien hingga Analisis DRPs,” MARAS: Jurnal Penelitian Multidisiplin, vol. 1, no. 3, pp. 400-412, 2023.
[8] Y. Shi, X. Zhang, T. Wong, T. Yan, L. Henry, R. Cheung and M. H. & Nguyen, “Sex differences in risk of adverse liver events in patients with cirrhosis,” JAMA Network Open, vol. 8, no. 7, pp. e2523674-e2523674, 2025.
[9] D. Tan, K. E. Chan, Z. Y. Wong, C. H. Ng, J. Xiao, W. H. Lim, P. Tay, A. Tang, C. E. Fu, M. Muthiah, B. Nah, E. X. Tan, M. L. P. Teng, M. S. Siddiqui, Y. Y. Dan, S. G. Lim and R. &. H. D. Q. Loomba, “Global Epidemiology of Cirrhosis: Changing Etiological Basis and Comparable Burden of Nonalcoholic Steatohepatitis between Males and Females,” Digestive diseases (Basel, Switzerland), vol. 41, no. 6, pp. 900-912, 2023.
[10] S. Ndraha, I. Imelda, M. Tendean and M. Santoso, “Komplikasi Penderita Sirosis Hati Di RSUD KOJA Pada Bulan Juli - November 2017,” J Kedokt Meditek, vol. 24, no. 67, pp. 17-20, 2019.
[11] L. N. Ahmad, H. A. M. Amran and A. Handriyati, “Temuan Kolelitiasis Pada Penderita Sirosis Hepatis Di RSU Anutapura Palu.,” Medika Alkhairaat: Jurnal Penelitian Kedokteran dan Kesehatan, vol. 4, no. 3, pp. 87-92, 2022.
[12] Z. M. Saleh, P. .. Bloom, K. Grzyb and E. B. Tapper, “How do patients with cirrhosis and their caregivers learn about and manage their health? A review and qualitative study,” Hepatology Communications, vol. 5, no. 2, pp. 168-176, 2021.
[13] M. Amalia, P. H. Hidayati, A. K. E. Yanti, S. Vitayani and S. W. Gayatri, “Karakteristik Pasien Sirosis Hepatis,” UMI Medical Journal, vol. 8, no. 1, pp. 53-61, 2023.
[14] A. Lovena, S. Miro and Efrida, “Karakteristik pasien sirosis hepatik di RSUP Dr. M. Djamil Padang,” Jurnal Kesehatan Andalas, vol. 6, no. 1, pp. 5-12, 2017.
[15] I. U. Ratnasekera, A. Johnson, E. E. Powell, A. Henderson, K. M. Irvine and P. C. & Valery, “Epidemiology of ascites fluid infections in patients with cirrhosis in Queensland, Australia from 2008 to 2017: A population-based study,” Medicine, vol. 101, no. 20, p. e29217, 2022.
[16] J. K. Jack, “Managing ascites in patients with cirrhosis,” JAAPA, vol. 36, no. 11, pp. 1-5, 2023.
[17] H. Yoshiji, S. Nagoshi, T. Akahane, Y. Asaoka, Y. Ueno, K. Ogawa and K. & Koike, “Evidencebased clinical practice guidelines for Liver Cirrhosis 2020,” Journal of gastroenterology, vol. 56, no. 7, pp. 593-619, 2021.
18] T. Mulyani, F. Rahmawati and N. & Ratnasari, “Evaluasi Penggunaan Kombinasi Spironolakton dan Furosemid pada Pasien Sirosis Hati dengan Ascites Permagna,” Jurnal Manajemen dan Pelayanan Farmasi, vol. 7, no. 2, pp. 97-99, 2017.
[19] R. Wang, L. Chai and X. Guo, “Diuretics in Cirrhotic Patients with Ascites,” in Pharmacotherapy for Liver Cirrhosis and Its Complications, Springer, 2022, pp. 167-178.
[20] D. E. Kaplan, C. Ripoll, M. Thiele, B. E. Fortune, D. A. Simonetto, G. Garcia-Tsao and J. & Bosch, “AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis,” Hepatology, vol. 79, no. 5, pp. 1180-1211, 2024.
[21] Y. An, Z. Bai, X. Xu, X. Guo, F. G. Romeiro, C. A. Philips, Y. Li, Y. Wu and X. & Qi, “ No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis,” BioMed research international, vol. 2020, no. 1, 2020.
[22] A. Mohanty and G. Garcia-Tsao, “Management of acute variceal bleeding,” Clinical liver disease, vol. 23, no. 1, 2024.
[23] A. Battle, J. Mudd, G. Ahlenstiel and E. & Kalo, “Liver Cirrhosis: Evolving Definitions, and Recent Advances in Diagnosis, Prevention and Management,” Livers, vol. 5, no. 3, 2025.
[24] N. Abu-Freha, T. Michael, L. Poupko, A. Estis-Deaton, M. Aasla, O. Abu-Freha, O. Etzion and L. & Nesher, “Spontaneous Bacterial Peritonitis among Cirrhotic Patients: Prevalence, Clinical Characteristics, and Outcomes,” Journal of clinical medicine, vol. 11, no. 1, p. 207, 2021.
[25] X. Lin and U. Kück, “Cephalosporins as key lead generation beta-lactam antibiotics,” Applied microbiology and biotechnology, vol. 106, no. 24, pp. 8007-8020, 2022.
[26] J. Huaringa-Marcelo, M. R. Huaman, A. Branez-Condorena, P. Villacorta-Landeo, D. F. Pinto-Ruiz, D. Urday-Ipanaque and A. & Lozano Miranda, “Vasoactive Agents for the Management of Acute Variceal Bleeding: A Systematic Review and Meta-analysis,” Journal of Gastrointestinal & Liver Diseases, vol. 30, no. 1, pp. 110-121, 2021.
[27] P. E. Rautou, S. H. Caldwell and E. & Villa, “Bleeding and thrombotic complications in patients with cirrhosis: a state-of-the-art appraisal.,” Clinical Gastroenterology and Hepatology, vol. 21, no. 8, pp. 2110-2123, 2023.
[28] D. Bates, J. Edwards, A. Langevin, A. Abu-Ulba, F. Yallou, B. Wilson and S. & Ghosh, “Rebleeding in Variceal and Nonvariceal Gastrointestinal Bleeds in Cirrhotic Patients Using Vitamin K1: The LIVER-K Study.,” The Canadian journal of hospital pharmacy, vol. 73, no. 1, pp. 19-26, 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nanda Aryani Putri, apt. Adam M. Ramadhan S. Farm., M. Sc. (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
